Phase II: Commercialization of a preclinical Magnetic Particle Imaging system with sub-millimeter resolution, nano-molar sensitivity, and integrated CT

第二阶段：具有亚毫米分辨率、纳摩尔级灵敏度和集成 CT 的临床前磁粒子成像系统的商业化

• 批准号: 9752545
• 负责人: Patrick Goodwill
• 金额: $ 73.07万
• 依托单位: MAGNETIC INSIGHT, INC.
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-05-01 至 2020-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9752545
• 关键词: 3-Dimensional; Aging; Anatomy; Animal Experimentation; Animals; Brain; Brain Neoplasms; Cardiovascular system; Cells; Clinical; Collaborations; Cone; Contrast Sensitivity; Detection; Development; Diagnosis; Diagnostic Imaging; Diagnostic radiologic examination; Discipline of Nuclear Medicine; Disease; Electronics; Fluorine; Frequencies; Grant; Heart Diseases; Heart failure; Home environment; Hour; Image; Imaging Techniques; Imaging technology; Immune; Infrastructure; Iron; Label; Light; Longevity; Magnetic Resonance Imaging; Magnetism; Malignant Neoplasms; Measures; Mechanics; Microglia; Modality; Modeling; Molecular Biology; Monitor; Morphologic artifacts; Mus; Noise; Optics; Organ; PET/CT scan; Phase; Physiologic pulse; Positron-Emission Tomography; Proteins; Radiation; Radioactive; Rattus; Research; Research Personnel; Resolution; Robotics; Scanning; Scientist; Signal Transduction; Site; Slice; Speed; Stroke; System; Systems Development; Technology; Testing; Therapeutic; Time; Tissues; Tracer; Universities; Work; X-Ray Computed Tomography; base; cancer imaging; cellular imaging; chimeric antigen receptor T cells; clinical application; clinically translatable; commercialization; cone-beam computed tomography; contrast imaging; design; design and construction; imager; imaging modality; imaging system; improved; in vivo; in vivo imaging; innovation; insight; instrument; iron oxide; magnetic field; millimeter; molecular imaging; mouse model; nanomolar; noninvasive diagnosis; nuclear imaging; optical imaging; particle; pre-clinical; pre-clinical research; prevent; prototype; single photon emission computed tomography; stem cell therapy; targeted imaging; tomography; tool

Abstract The two dominant preclinical molecular imaging techniques, optical imaging and nuclear imaging, have technical limitations that hamper their use in applications requiring high resolution, longitudinal tracer imaging with absolute quantitation. We are developing a new molecular imaging modality, Magnetic Particle Imaging (MPI), which does not have these limitations and is capable of: nanomolar sensitivity, absolute quantitation of a tracer, resolution independent of depth, and monitoring a stable tracer for weeks to months. These capabilities make MPI complementary to existing molecular imaging techniques and give scientists a versatile new tool when imaging cancer, tracking therapeutic and immune cells, and imaging the cardiovascular system. MPI is best compared with nuclear medicine, in that both modalities “see” only the injected tracer, “see” right through background tissue, and are translatable. The MPI technique works by directly detecting the nonlinear magnetization of iron-oxide tracers using low- frequency magnetic fields. MPI’s method of direct detection is exquisitely sensitive and we have already demonstrated micro-molar sensitivities in prototype systems. Indeed, the theoretical sensitivity limit of MPI may be as low as a single tagged cell in a voxel. MPI is unrelated to Magnetic Resonance Imaging (MRI), and MPI scans cannot be acquired using a MRI imager. This project aims to develop the first MPI system tailored for pre-clinical researchers working with mouse and rat models. The proposed system will be the world’s highest sensitivity and highest resolution tomographic MPI scanner, as well as the first MPI system with integrated CT. First, we will build a high strength field free line magnetic field gradient mounted to a rotating gantry to enable tomographic MPI imaging. We will then integrate CT to enable acquisition of a tissue reference image. Last, we will test the imager in vivo with mouse and rat models.

摘要 两种主要的临床前分子成像技术，光学成像和核成像， 成像，具有技术限制，阻碍了它们在要求高分辨率的应用中的使用。 分辨率，纵向示踪剂成像与绝对定量。我们正在开发一种新的 分子成像模式，磁粒子成像（MPI），它没有这些 局限性，并能够：纳摩尔灵敏度，绝对定量示踪剂，分辨率 独立于深度，并监测稳定的示踪剂数周至数月。这些能力 使MPI成为现有分子成像技术的补充，并为科学家提供 多功能的新工具，当成像癌症，跟踪治疗和免疫细胞，成像 心血管系统 MPI与核医学相比是最好的，因为这两种方式都只“看到” 注射的示踪剂，“看到”通过背景组织，并且是可平移的。MPI技术 工作原理是直接检测非线性磁化的氧化铁示踪剂使用低， 频率磁场MPI的直接检测方法非常灵敏， 已经在原型系统中证明了微摩尔灵敏度。事实上，理论上 MPI灵敏度极限可以低至体素中的单个标记细胞。MPI与 磁共振成像（MRI）和MPI扫描无法使用MRI成像仪采集。 该项目旨在开发第一个为临床前研究人员量身定制的MPI系统 用小鼠和大鼠模型进行研究。拟议中的系统将是世界上灵敏度最高的 和最高分辨率的断层MPI扫描仪，以及第一个集成了 CT.首先，我们将建立一个高强度场自由线磁场梯度安装到一个 旋转机架以实现断层摄影MPI成像。然后，我们将整合CT， 获取组织参考图像。最后，我们将在小鼠和大鼠体内测试成像仪 模型